Long cycle-life wound lithium-ion battery cells having metallized film current collectors
US-2024358635-A1 · Oct 31, 2024 · US
Use of flavone compound for prevention or treatment of obesity
US9511048B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9511048-B2 |
| Application number | US-201514541389-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 4, 2015 |
| Priority date | May 16, 2012 |
| Publication date | Dec 6, 2016 |
| Grant date | Dec 6, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition containing flavone compound as an active ingredient for treating obesity, and more specifically to a pharmaceutical composition for preventing or treating obesity and a dietary composition for preventing or reducing obesity containing 5,7-dimethoxyflavone or 5,7,4′-trimethoxyflavone. The compound according to the present invention inhibits adipogenesis, and reduces expression of the key transcription factors (SREBP1c and C/EBP) related to lipogenesis and of enzyme proteins (FAS and ACC) related to adipogenesis, and thus is effective in preventing or treating obesity.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating obesity, the method comprising administering an effective amount of a compound represented by Formula 1 or a salt thereof to a subject in need of obesity treatment wherein each of R 1 , R 2 , and R 3 consists of hydrogen or a methoxy croup. 2. The method of claim 1 , wherein the compound is 5,7-dimethoxyflavone or 5,7,4′-trimethoxyflavone. 3. The method of claim 1 , wherein administering an effective amount of the compound comprises administering 0.001 to 300 mg/day/kg of body weight of the compound, or the salt thereof, to the subject in need of obesity treatment.
Assignees
Inventors
Classifications
Anorexiants; Antiobesity agents · CPC title
Plant extracts, their artificial duplicates or their derivatives · CPC title
containing oxygen or sulfur as hetero atom · CPC title
- A61K31/353Primary
3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title
Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9511048B2 cover?
- The present invention relates to a pharmaceutical composition containing flavone compound as an active ingredient for treating obesity, and more specifically to a pharmaceutical composition for preventing or treating obesity and a dietary composition for preventing or reducing obesity containing 5,7-dimethoxyflavone or 5,7,4′-trimethoxyflavone. The compound according to the present invention in…
- Who is the assignee on this patent?
- Industry-Academic Cooperation Foundation Yonsei Univ
- What technology area does this patent fall under?
- Primary CPC classification A61K31/353. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).